In studies in primary human leukemia specimens, subtypes of leukemias with elevated levels of eIF4E are sensitive to inhibition of eIF4E by antagonists at levels 100-fold less than those that effect normal bone marrow or other leukemic subtypes [38]. Here, EIF4E is linked to leukemia.